The PSMA-targeted radioligand, 177Lu-PSMA-617, has been clinically tested in the therapy of PCa since 2015 (Hennrich and Eder 2022) and has been approved by FDA and EMA in 2022 for treatment of patients with metastatic castration-resistant PCa (Sartor et al. 2021). This evidence concerns the gene FOLH1 and posterior cortical atrophy.